The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss for the period | -115,915 | -1,057,431 |
| Loss on liability settlement | 0 | -801,193 |
| Accounts payable and accrued expenses | 243 | 1,630 |
| Accrued board of directors compensation | 104,551 | 211,500 |
| Net cash flows used in operating activities | -11,121 | -43,108 |
| Proceeds from related parties | 11,000 | 43,151 |
| Capital contributions | - | 0 |
| Net cash flows provided by financing activities | 11,000 | 43,151 |
| Cash flows from investing activities | - | 0 |
| Net change in cash | -121 | 43 |
| Cash and cash equivalents at beginning of period | 862 | - |
| Cash and cash equivalents at end of period | 784 | - |
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)